Senate’s US FDA User Fee Bill Answers Biosimilar Interchangeable Exclusivity Questions

 
• By Derrick Gingery
  
biologic
The Senate bill would address some biosimilar questions, but others still linger • Source: Shutterstock

More from Biosimilars

More from Products